GlaxoSmithKline’s (GSK) “Buy” Rating Reiterated at Liberum Capital

Liberum Capital restated their buy rating on shares of GlaxoSmithKline (LON:GSK) in a research report report published on Wednesday, February 7th. Liberum Capital currently has a GBX 1,630 ($22.52) price objective on the stock.

GSK has been the topic of several other reports. Goldman Sachs Group reissued a buy rating and issued a GBX 1,900 ($26.25) target price on shares of GlaxoSmithKline in a report on Tuesday, October 17th. S&P Global set a GBX 1,500 ($20.72) price objective on shares of GlaxoSmithKline and gave the stock a neutral rating in a research report on Thursday, October 26th. HSBC restated a buy rating and issued a GBX 1,925 ($26.60) price objective on shares of GlaxoSmithKline in a research report on Wednesday, November 22nd. Morgan Stanley set a GBX 1,450 ($20.03) target price on shares of GlaxoSmithKline and gave the company a sell rating in a research report on Monday, November 6th. Finally, Kepler Capital Markets decreased their price target on shares of GlaxoSmithKline from GBX 1,520 ($21.00) to GBX 1,340 ($18.51) and set a reduce rating for the company in a report on Wednesday, November 1st. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of GBX 1,540.45 ($21.28).

GlaxoSmithKline (LON:GSK) traded up GBX 10.40 ($0.14) during midday trading on Wednesday, reaching GBX 1,301.20 ($17.98). The company’s stock had a trading volume of 4,296,016 shares, compared to its average volume of 9,780,000. The firm has a market capitalization of $64,420.00 and a P/E ratio of 4,197.42. GlaxoSmithKline has a 12 month low of GBX 1,235.20 ($17.07) and a 12 month high of GBX 1,724.50 ($23.83).

The firm also recently declared a dividend, which will be paid on Thursday, April 12th. Stockholders of record on Thursday, February 22nd will be paid a dividend of GBX 23 ($0.32) per share. The ex-dividend date is Thursday, February 22nd. This represents a dividend yield of 1.78%. This is an increase from GlaxoSmithKline’s previous dividend of $19.00.

In other GlaxoSmithKline news, insider Victoria Whyte sold 5,199 shares of GlaxoSmithKline stock in a transaction on Monday, February 12th. The shares were sold at an average price of GBX 1,295 ($17.89), for a total value of £67,327.05 ($93,018.86). Also, insider Patrick Vallance sold 20,000 shares of GlaxoSmithKline stock in a transaction on Monday, December 18th. The shares were sold at an average price of GBX 1,310 ($18.10), for a total transaction of £262,000 ($361,978.45). Insiders have bought 590 shares of company stock valued at $754,966 in the last ninety days.

ILLEGAL ACTIVITY WARNING: “GlaxoSmithKline’s (GSK) “Buy” Rating Reiterated at Liberum Capital” was originally reported by Week Herald and is the property of of Week Herald. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://weekherald.com/2018/02/15/glaxosmithklines-gsk-buy-rating-reaffirmed-at-liberum-capital.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply